Literature DB >> 17251547

Antimyelin antibodies with no progression to multiple sclerosis.

Raul Pelayo, Mar Tintoré, Xavier Montalban, Alex Rovira, Carmen Espejo, Markus Reindl, Thomas Berger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17251547     DOI： 10.1056/NEJMc062467

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

1.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

Review 2.  Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice.

Authors:  Amanda Marchionatti; Mark Woodhall; Patrick Joseph Waters; Douglas Kazutoshi Sato
Journal:  Neurol Sci       Date:  2020-10-15       Impact factor: 3.307

Review 3.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 4.  B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases.

Authors:  Katherine A McLaughlin; Kai W Wucherpfennig
Journal:  Adv Immunol       Date:  2008       Impact factor: 3.543

5.  Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis.

Authors:  M S Freedman; C Metzig; L Kappos; C H Polman; G Edan; H-P Hartung; D H Miller; X Montalban; J Yarden; L Spector; E Fire; N Dotan; S Schwenke; V Lanius; R Sandbrink; C Pohl
Journal:  Mult Scler       Date:  2011-12-19       Impact factor: 6.312

6.  Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis.

Authors:  Jeremy Sokolove; Reuven Bromberg; Kevin D Deane; Lauren J Lahey; Lezlie A Derber; Piyanka E Chandra; Jess D Edison; William R Gilliland; Robert J Tibshirani; Jill M Norris; V Michael Holers; William H Robinson
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

7.  MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.

Authors:  Patrick Waters; Mark Woodhall; Kevin C O'Connor; Markus Reindl; Bethan Lang; Douglas K Sato; Maciej Juryńczyk; George Tackley; Joao Rocha; Toshiyuki Takahashi; Tatsuro Misu; Ichiro Nakashima; Jacqueline Palace; Kazuo Fujihara; M Isabel Leite; Angela Vincent
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-03-19

Review 8.  Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases.

Authors:  Christine Riedhammer; Robert Weissert
Journal:  Front Immunol       Date:  2015-06-17       Impact factor: 7.561

Review 9.  B cells in autoimmune and neurodegenerative central nervous system diseases.

Authors:  Joseph J Sabatino; Anne-Katrin Pröbstel; Scott S Zamvil
Journal:  Nat Rev Neurosci       Date:  2019-11-11       Impact factor: 34.870

10.  Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products.

Authors:  Zhiqun Zhang; J Susie Zoltewicz; Stefania Mondello; Kimberly J Newsom; Zhihui Yang; Boxuan Yang; Firas Kobeissy; Joy Guingab; Olena Glushakova; Steven Robicsek; Shelley Heaton; Andras Buki; Julia Hannay; Mark S Gold; Richard Rubenstein; Xi-Chun May Lu; Jitendra R Dave; Kara Schmid; Frank Tortella; Claudia S Robertson; Kevin K W Wang
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.